PACB — Pacific Biosciences Of California Income Statement
0.000.00%
Last trade - 00:00
- $497.37m
- $880.41m
- $200.52m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 90.9 | 78.9 | 131 | 128 | 201 |
Cost of Revenue | |||||
Gross Profit | 34.6 | 32.6 | 58.9 | 52.7 | 56.2 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 173 | 51.3 | 393 | 436 | 537 |
Operating Profit | -82.5 | 27.6 | -262 | -307 | -337 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -84.1 | 29.4 | -275 | -314 | -318 |
Provision for Income Taxes | |||||
Net Income After Taxes | -84.1 | 29.4 | -181 | -314 | -307 |
Net Income Before Extraordinary Items | |||||
Net Income | -84.1 | 29.4 | -181 | -314 | -307 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -84.1 | 29.4 | -181 | -314 | -307 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.67 | -0.586 | -0.623 | -1.38 | -1.17 |